Hightechbio

Suzhou Hightechbio Biotechnology (Hightechbio) is a clinical-stage biotechnology company based in China that specializes in the development of advanced drug delivery systems and innovative cell therapies. The company is primarily known for its proprietary mPEG-PDLLA polymeric micelle platform, which is designed to improve the solubility, safety, and therapeutic index of traditional chemotherapy agents. Its lead candidate, a polymeric micelle formulation of docetaxel, is currently in Phase 2 clinical trials for the treatment of solid tumors under a global strategic partnership with Simcere Pharmaceutical Group. In addition to its nanomedicine portfolio, Hightechbio is advancing a pipeline of CAR-T cell therapies targeting CD19 and BCMA for various hematologic malignancies. The company operates as a key technology provider, bridging the gap between innovative formulation science and large-scale pharmaceutical commercialization.